HIMS Hims & Hers Health Inc

$HIMS that we are trading about the value after the Novo deal was struck, makes abselutly no sense… in between: -eucalyptus -hims live in australia and germany -testorstone -peptides -eli lly deal -reacceleration in us Should be trading a lot higher than the current Price, very excited for tommorrows ER!💎🙌🎁

$HIMS bout to go sub $5B market cap as revenue and subscriptions explode worldwide. Lol ahhaha in 5 years barring end of world from ww3, this will be a 100b min market cap. Buy and hold

$HIMS After the Internet/dot-com boom and AI, the next 10 years will be dominated by longevity and medicine/genetics. I will therefore gradually increase my position and hold it for 5–10 years without touching, with the goal of selling at over 500 per share. In my opinion, HIMS will be one of the leading and dominant players thanks to its business model and strategies. Have a wonderful Sunday, everyone who has invested.

$HIMS: Hims & Hers Health expands access to Lilly's obesity medicines through its platform, with self-pay pricing starting at $149 monthly.

$HIMS I really don't like that the stock price went below the support line. At the same time, they have had all good news and I feel this drop is mostly due to a full market correction rather than HIMS itself. Earnings are next week and I think they will have a lot of good things to say, lots of bad things will be in the past or already prepared for (like their $60 million set aside for lawsuits already factored into last quarters numbers). I expect this stock to rally after earnings and possibly never look back. With all these catalysts (peptides Eli Lilly), it's possible investors looked past the lawsuits and start drooling over the future of this company.

$HIMS Well, they put a link to peptides on the front banner. Let me just put that Karen wig away. Don't know when we'll need that again.

$HIMS lmao Stocktwits wondering the same thing…. Crazy stupid price action. You’re telling me there has been no positive news to move this stock higher? Clown show

$HIMS One positive thing about upcoming earnings is that we won’t have to worry about 80M worth of legal contingency fees and Eucalyptus acquisition costs dragging down our bottom line like in Q2. Barring any unexpected expenses we should be pretty close to breakeven on a GAAP basis on Monday.

$HIMS Not sure if you knew this but I heard through a friend of a guy I know that a partnership with Eli Lily is a big deal.

$HIMS Scraping peptide beauty youtube channels and performing named entity recognition for GHK-CU in the comments. Why? A lot of these commenters reveal what peptides they're on. If you go through enough videos and hit 55,555 unique commenters using one specific peptide, that is a potential $100 million dollar product for Hims. Raw doggin TAMs.

$HIMS YESSSS LFFFGGG HIMSTER FAM. I LOVE YOU ALL. WE HEADED TO MARS ,THE MOON NOT FAR ENOUGH!!!!!! $HIMZ

$HIMS Wont be satisfied until this breaks over 33 minimum, been held down for way too long

$HIMS peptides approved ! The news we’ve been waiting all year. Here’s a nice 5-10% red day lmao 😂

$HIMS Started my position here today with a dip buy at $23.23. Today is the kind of market I love to buy stocks when there’s blood 🩸 in the streets.

Hims & Hers Health announced a direct partnership with Eli Lilly to distribute its obesity treatments, including injectable Zepbound and newly launched oral Foundayo, through its telehealth platform for cash-pay prices of $299 and $149 per month, respectively. The agreement allows patients to consult licensed providers, obtain prescriptions and receive FDA-approved medications directly through Hims & Hers, eliminating the need to use Lilly's separate direct-pay platform. The deal expands Hims & Hers' branded GLP-1 offering to include products from both major obesity-drug manufacturers, following a similar March 2026 partnership with Novo Nordisk for Wegovy and Ozempic. The move reinforces its strategic shift away from compounded weight-loss drugs toward branded, FDA-approved treatments. Investors are also positioning ahead of Q3 results on November 9, with revenue expected at approximately $892.9M and potential updates on its GLP-1 strategy. $HIMS $LLY $NVO

$HIMS $HIMS we wil not see the 15x like we did with the compunded glp-1 Golden times because of the new peptides offerimgs, not at all, how Ever no guidence includes the Selling of any peptides, so guidence is likely to get raised. And the margins like u Said with glp-1 will be very nice orobaly in the High 70 to low 80s And I know not every hims subscriber in the us will jump the train. I belive that people using peptides would choose to pay more for regulated and us made peptides vs grey/black market, where a lot of Them has been contaminated with bactairia or dont even contain what they claim! The reasons why Big Pharma dont do em is beacuse they are very hard to patent in the first place, beacuse they are a natrual part of our body. And with hims being the Only pharmacies with a manufacture in the us, I see High upside with this new “legal” market (at the moment). I Think it was JP Morgan or some bank that claimed bpc-153 was a 1,5-3b usd market, anyway

$HIMS this, again, will eaise guidance Mon. 1. International 2. Peptides 3. Lily 4. First full quarter of branded glp1’s to base new guidance on 💰💰💰💰

$HIMS i believe lily’s deal shows the succes we will see Monday. Novo sales are doing great, Lily wants to join.

$HIMS Wegovy pill got approved in Australia. Should be launching about Christmas time. Throwing this out there... Hear me out on this.... Wegovy Gift Cards Everyone has a fatty in their life that they want to stay alive, but don't know how to tell them that they love them. Sure this person will probably never talk to you again, but that's the price we pay for love.

$HIMS LLY will be over $100B revenue FY27; HIMS grabbing a piece of that pie. Novo $46B revenue FY27; HIMS grabbing a piece of that pie. Peptide sales CY2027 $2.5-3.5B; HIMS grabbing a piece of that pie.